share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

福泰製藥 | 4:持股變動聲明-高管 Tatsis Ourania
美股SEC公告 ·  06/05 16:13
Moomoo AI 已提取核心訊息
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
2024年6月3日,Vertex Pharmaceuticals Inc. (VRTX)的執行副總裁、首席監管與質量官Ourania Tatsis以每股460美元的價格完成了2,175股普通股的出售。該交易在公開市場進行,總價值為1,005,000美元。此次出售是一筆直接擁有交易,也是投資調整正常的一部分,出售後,Tatsis在公司擁有49,098股股份。
2024年6月3日,Vertex Pharmaceuticals Inc. (VRTX)的執行副總裁、首席監管與質量官Ourania Tatsis以每股460美元的價格完成了2,175股普通股的出售。該交易在公開市場進行,總價值為1,005,000美元。此次出售是一筆直接擁有交易,也是投資調整正常的一部分,出售後,Tatsis在公司擁有49,098股股份。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息